BIORA THERAPEUTICS, INC.: Nasdaq/NYSE listing notice — Biora Therapeutics cures Nasdaq bid price deficiency; delisting hearing cancelled

BIORA THERAPEUTICS, INC.

Received Nasdaq compliance letter on Jan 19, 2023 confirming bid price deficiency cured.
Company now in compliance with all applicable continued listing standards.
Scheduled delisting hearing before Nasdaq Hearings Panel cancelled.
Common stock (BIOR) will continue trading on The Nasdaq Global Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIORA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price.

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price

Exact text from the filing

January 19, 2023, Biora Therapeutics, Inc. (the “ Company ”) received a letter (the “ Compliance Letter ”) from Nasdaq notifying the Company that (i) the Company’s previously announced bid price deficiency had been cured and (ii) the Company was in compliance with all applicable continued listing standards. Accordingly, the Compliance Letter provided that the Company’s scheduled hearing had been cancelled. As previously disclosed, in December 2022, the Company received a determination from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that, due to the Company’s contin

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-011988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.